IS5040A - B - seyting peptíðhluta lipópróteins/MTP (netkorna tríglýserið tilfærsluprótein hindrandi amíð - Google Patents

B - seyting peptíðhluta lipópróteins/MTP (netkorna tríglýserið tilfærsluprótein hindrandi amíð

Info

Publication number
IS5040A
IS5040A IS5040A IS5040A IS5040A IS 5040 A IS5040 A IS 5040A IS 5040 A IS5040 A IS 5040A IS 5040 A IS5040 A IS 5040A IS 5040 A IS5040 A IS 5040A
Authority
IS
Iceland
Prior art keywords
mtp
lipoprotein
secretion
peptide moiety
moiety
Prior art date
Application number
IS5040A
Other languages
English (en)
Inventor
Chang George
Joseph Quallich George
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS5040A publication Critical patent/IS5040A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5040A 1996-11-27 1999-04-30 B - seyting peptíðhluta lipópróteins/MTP (netkorna tríglýserið tilfærsluprótein hindrandi amíð IS5040A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3230796P 1996-11-27 1996-11-27
PCT/IB1997/001368 WO1998023593A1 (en) 1996-11-27 1997-11-03 Apo b-secretion/mtp inhibitory amides

Publications (1)

Publication Number Publication Date
IS5040A true IS5040A (is) 1999-04-30

Family

ID=21864233

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5040A IS5040A (is) 1996-11-27 1999-04-30 B - seyting peptíðhluta lipópróteins/MTP (netkorna tríglýserið tilfærsluprótein hindrandi amíð

Country Status (34)

Country Link
US (1) US6121283A (is)
EP (1) EP0944602A1 (is)
JP (1) JP3270764B2 (is)
KR (1) KR100334567B1 (is)
CN (2) CN1238764A (is)
AP (1) AP804A (is)
AR (1) AR010309A1 (is)
AU (1) AU716151B2 (is)
BG (2) BG103434A (is)
BR (1) BR9714364A (is)
CA (1) CA2272719C (is)
CZ (1) CZ292160B6 (is)
DZ (1) DZ2358A1 (is)
EA (1) EA001539B1 (is)
GT (1) GT199700122A (is)
HN (1) HN1997000144A (is)
HR (1) HRP970642A2 (is)
ID (1) ID18995A (is)
IL (1) IL129744A0 (is)
IS (1) IS5040A (is)
MA (1) MA26451A1 (is)
NO (1) NO312760B1 (is)
NZ (1) NZ335162A (is)
OA (1) OA11050A (is)
PA (1) PA8441601A1 (is)
PE (1) PE17199A1 (is)
SK (1) SK65499A3 (is)
TN (1) TNSN97193A1 (is)
TR (1) TR199901180T2 (is)
TW (1) TW502023B (is)
UY (1) UY24789A1 (is)
WO (1) WO1998023593A1 (is)
YU (1) YU23499A (is)
ZA (1) ZA9710641B (is)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
DK0832069T3 (da) * 1995-06-07 2003-04-22 Pfizer Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
SK4782001A3 (en) 1998-10-08 2001-11-06 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
DK1140184T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
EP1342475A1 (en) * 1998-12-23 2003-09-10 G.D. Searle LLC. Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
CN1342091A (zh) * 1998-12-23 2002-03-27 G.D.瑟尔有限公司 心血管指征的联合用药
DE19929065A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19929012A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
DE19929031A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
WO2001005767A1 (en) * 1999-07-20 2001-01-25 Novartis Ag Organic compounds
CA2324800A1 (en) * 1999-11-10 2001-05-10 Mary Anne Hickman Use of apo b secretion/mtp inhibitors
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
CO5271688A1 (es) * 1999-11-10 2003-04-30 Pfizer Prod Inc Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
US6878707B2 (en) 2000-01-18 2005-04-12 Novartis Ag Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
AU6011301A (en) * 2000-03-14 2001-09-24 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinoline derivatives
AU2001262185A1 (en) * 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
AU2001277727A1 (en) * 2000-08-10 2002-02-25 Tanabe Seiyaku Co., Ltd. Benzoylaminoisoindoline compounds, processes for the preparation of the same andintermediates for the synthesis thereof
AU2001277728A1 (en) * 2000-08-10 2002-02-25 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
HUP0301728A3 (en) * 2000-09-01 2004-05-28 Sankyo Co Hmg-coa reductase inhibiting pharmaceutical compositions and their use
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
RU2003112691A (ru) * 2000-10-05 2004-09-20 Фудзисава Фармасьютикал Ко.,Лтд. (Jp) Бензамидные соединения в качестве ингибиторов секреции аро в
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
US20040157866A1 (en) * 2001-04-30 2004-08-12 Hisashi Takasugi Amide compounds
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
CN1880304B (zh) * 2001-06-28 2010-11-24 辉瑞产品公司 三酰胺取代的吲哚、苯并呋喃及苯并噻吩
AU2002322585A1 (en) * 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
US20030130343A1 (en) * 2001-08-10 2003-07-10 Adipogenix, Inc. Fat accumulation-modulating compounds
US20050038035A1 (en) * 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
AU2003207431A1 (en) 2002-01-17 2003-09-02 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
KR100664822B1 (ko) 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
CN1630629B (zh) 2002-02-28 2010-05-05 日本烟草产业株式会社 酯化合物及其医药用途
US7241774B2 (en) * 2002-03-13 2007-07-10 University Of Tennessee Research Foundation Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
EP1578725A1 (en) * 2002-12-20 2005-09-28 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
CA2510815A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
AU2004222436A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
JP4832897B2 (ja) 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
JP4094050B2 (ja) 2004-03-01 2008-06-04 アクテリオン ファーマシューティカルズ リミテッド 置換１，２，３，４−テトラヒドロイソキノリン誘導体
NZ549721A (en) 2004-03-05 2010-08-27 Univ Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
BRPI0516772A (pt) * 2004-10-25 2008-09-23 Japan Tobacco Inc formulação sólida com solubilidade e estabilidade melhoradas e método para produção da referida formulação
EP1843819A2 (en) * 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
AU2005308575A1 (en) 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
EA024768B1 (ru) 2005-04-19 2016-10-31 Сюрфэйс Лоджикс, Инк. Ингибиторы белка микросомального транспорта триглицеридов и секреции апо-в
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
JP2009531314A (ja) * 2006-03-10 2009-09-03 ニューロジェン・コーポレーション ピペラジニルオキソアルキルテトラヒドロイソキノリン類および関連類似物
EP2261333B1 (en) * 2006-04-03 2016-03-30 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
EP2037929A4 (en) * 2006-06-02 2010-02-17 Univ San Diego State Res Found COMPOSITIONS AND METHODS FOR REDUCING HYPERLIPIDEMIA
EP2076597A2 (en) * 2006-10-09 2009-07-08 Santaris Pharma A/S Rna antagonist compounds for the modulation of pcsk9
CL2007002958A1 (es) * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
JP5525261B2 (ja) * 2006-10-24 2014-06-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｔｐ阻害性テトラヒドロ−ナフタレン−１−カルボン酸誘導体
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
WO2008075949A1 (en) * 2006-12-20 2008-06-26 Friesland Brands B.V. Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
DK2149605T3 (da) * 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
AU2008228243B2 (en) * 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
AU2008268442A1 (en) * 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
WO2009027527A2 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S Rna antagonist compounds for the modulation of fabp4/ap2
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
CA2707549A1 (en) 2007-12-03 2009-06-11 Itzik Harosh Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
KR20100102646A (ko) 2007-12-11 2010-09-24 가부시키가이샤 사이토파스파인더 카르복스아미드 화합물 및 케모카인 수용체 길항제로서의 이의 용도
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
JP5773535B2 (ja) * 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
AU2014300981B2 (en) 2013-06-27 2017-08-10 Ricc A/S Antisense oligomers and conjugates targeting PCSK9
US9856478B2 (en) 2013-10-30 2018-01-02 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of obesity, metabolic syndrome, and atherosclerosis
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3209299A4 (en) 2014-10-22 2018-04-04 The Board of Regents of The University of Texas System Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
EP4188372A1 (en) 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
CA3212863A1 (en) * 2021-03-26 2022-09-29 Laura Carzaniga Indoline derivatives as ddr1 and ddr2 inhibitors
EP4313972B1 (en) * 2021-03-26 2025-01-29 Chiesi Farmaceutici S.p.A. Indoline derivatives as ddrs inhibitors
CN113292493A (zh) * 2021-06-23 2021-08-24 上海立科化学科技有限公司 5,7-二氯-1,2,3,4-四氢异喹啉的制备方法
WO2024216197A2 (en) * 2023-04-13 2024-10-17 Acelot, Inc. Compounds and methods for treating protein aggregation diseases
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION

Also Published As

Publication number Publication date
EA001539B1 (ru) 2001-04-23
KR20000057269A (ko) 2000-09-15
NO992525D0 (no) 1999-05-26
BG103434A (en) 2000-07-31
TW502023B (en) 2002-09-11
OA11050A (en) 2002-03-07
US6121283A (en) 2000-09-19
NO312760B1 (no) 2002-07-01
BR9714364A (pt) 2000-03-21
ID18995A (id) 1998-05-28
HN1997000144A (es) 1997-12-16
CZ292160B6 (cs) 2003-08-13
TR199901180T2 (xx) 1999-08-23
JP2000505810A (ja) 2000-05-16
JP3270764B2 (ja) 2002-04-02
KR100334567B1 (ko) 2002-05-03
IL129744A0 (en) 2000-02-29
PA8441601A1 (es) 2000-05-24
CA2272719C (en) 2002-10-01
AU4634797A (en) 1998-06-22
EA199900416A1 (ru) 1999-12-29
HRP970642A2 (en) 1998-10-31
UY24789A1 (es) 2000-09-29
PE17199A1 (es) 1999-02-19
GT199700122A (es) 1999-05-19
CN1238764A (zh) 1999-12-15
TNSN97193A1 (fr) 2005-03-15
SK65499A3 (en) 2001-05-10
AP804A (en) 2000-01-28
DZ2358A1 (fr) 2002-12-28
ZA9710641B (en) 1999-05-26
AU716151B2 (en) 2000-02-17
NZ335162A (en) 2000-01-28
CA2272719A1 (en) 1998-06-04
CN1380289A (zh) 2002-11-20
MA26451A1 (fr) 2004-12-20
AR010309A1 (es) 2000-06-07
NO992525L (no) 1999-05-26
EP0944602A1 (en) 1999-09-29
WO1998023593A1 (en) 1998-06-04
YU23499A (sh) 2001-07-10
BG108830A (bg) 2005-10-31
AP9701145A0 (en) 1998-01-31

Similar Documents

Publication Publication Date Title
EP0853483A4 (en) NEW PEPTIDES
EP1017682A4 (en) NEW ANGIOGENESIS INHIBITORS
EP0984692A4 (en) ANGIOGENESIS INHIBITORS
DK0845003T3 (da) Hidtil ukendte opioid-peptider
NO992525L (no) Apo-B-sekresjon/MTP-inhiberings-amider
DE69824508D1 (de) Fernsprechbasiertes Anweisungssystem
FI961350L (fi) Hapteenimerkityt peptidit
FI974422A7 (fi) Lipoproteiinien ilmentäminen
NO985680L (no) Peptidderivater
EP0867448A4 (en) PEPTID which suppresses the 1xBalpha PHOSPHORY READING
IS4459A (is) Ný peptíð er hafa ónæmisbreytandi áhrif
NO983849L (no) Peptidderivater
FI970168A0 (fi) Peptidejä
FI964363L (fi) Peptidejä
ITBO960063A0 (it) Composti ad attivita' di fissaggio di gas
EP0821694A4 (en) CONOTOXIN PEPTIDE
BR9606756A (pt) Peptídeo
NO981052D0 (no) Peptidderivater
DE69720266D1 (de) Vielfältig verzweigte peptidkonstruktionen
NO981051D0 (no) Peptidderivater
KR980005843U (ko) 발신자 전화번호 표시 장치
IT244003Y1 (it) Tenuta d'albero
DE69606851D1 (de) Kultivierung von Petunia
DK28696A (da) Forbindelser af peptidtype
SE9504467D0 (sv) Peptide